Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

pAdVAntageā„¢ Vector Technical Bulletin

Instructions for Use of Product(s)
E1711

Literature # TB207

Cotransfection of mammalian cells with the pAdVAntage™ Vector enhances transient protein expression in a variety of cell types by increasing translation initiation. Transfection of mammalian cells with an expression vector often results in suboptimal expression of the protein of interest. Double-stranded RNA (dsRNA)generated during transfection is thought to activate the dsRNA-activated inhibitor (DAI), one of several enzymes involved in the host cell antiviral defense system. DAI phosphorylates the translation initiation factor eIF-2, halting translation and therefore protein production.
However, inhibition of translation by DAI can be overcome with the adenoviral Virus Associated I RNA (VAI RNA) that is produced by RNA polymerase III following co-transfection with the pAdVAntage™ Vector. The VAI RNA binds to DAI, preventing its activation, thereby allowing translation and protein expression. The pAdVAntage™ Vector contains base pairs 9,831–11,555 of the adenovirus type 2 genome on a 1,724bp SalI-HindIII fragment that encodes the virus-associated RNA genes, VAI and VAII.

Printed in USA. Revised 11/06.